Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.

Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance